INTRODUCTION AND OBJECTIVES: In recent years, multiparametric MRI (mpMRI) has gained increased acceptance and utilization as a diagnostic and staging tool for early -stage prostate cancer. Reporting systems, in particular the Prostate Imaging -Reporting and Data System (PI-RADS), now in its second version, has been advanced as means to standardize the grading and reporting of MRI findings. However, it remains to be determined whether PI-RADS scores independently predict the risk of adverse pathology, i.e. high-grade and/or high-stage disease. Objective: To evaluate the association of surgical pathological findings assessed on whole-mount pathology analysis and pre-operative mpMRI suspicion assessed using PI-RADS v2 scores.
METHODS: We retrospectively analyzed 121 patients who had radical prostatectomy within 12 months of their staging endorectal 3T mpMRI. We examined the association of the PI-RADS v2 scores with adverse surgical pathology, defined as advanced pathologic stage ( pT3a) or high-grade disease (primary Gleason pattern 4) or both, using frequency tables (diagnostic accuracy and chi-square) and logistic regression models.
RESULTS: Of 121 patients, 73 (60%) had adverse surgical pathology; 9 men (7%) had high-grade, 64 (29%) had pT3 disease, and 29 (24%) had both high-grade and high-stage disease. 106 (88%) had PI-RADS mpMRI score 4 or 5 findings, of whom, 65% had adverse pathology compared to 15 (12%) patients with PI-RADS 3, of whom 27% had adverse pathology. Conversely, 95% (69/73) of patients with adverse pathology had positive MR studies (PI-RADS score 4 or 5). Accordingly, mpMRI PI-RADS 4 or 5 demonstrated 95% sensitivity (95% CI 87-98), 23% specificity (95% CI 12-37), 65% PPV (95% CI 55-74), 73% NPV (95% CI 45-92), and 66% accuracy (95% CI 57-75) for the detection of adverse surgical pathology. In the multivariable logistic regression analysis, adjusted for PSA density and age, PI-RADS score 4 or 5 (odds ratio (OR) 4.1, 95% CI 1.2-14.2, p¼0.027) and clinical CAPRA score (OR 1.4, 95% CI 1.0-1.9, p¼0.026) were significantly and independently associated with higher risk of adverse pathology. This study is limited by its retrospective nature.
CONCLUSIONS: PI-RADS v2 score 4 or 5 on mpMRI is highly sensitive for the detection and prediction of adverse pathology. PI-RADS v2 may help improve the detection and staging of prostate cancer and allow for tailored intervention.
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PD65-12 THE ANDROGEN RECEPTOR BECOMES A NOVEL PREDICTIVE BIOMARKER OF PROSTATE CANCER PROGRESSION WHEN POST TRANSLATIONALLY ACTIVATED BY THE FER KINASE ON TYROSINE 223
Turki Altaylouni*, Fatima Zouanat, Eleonora Scarlata, Tarik Benidir, Lucie Hamel, Fadi Brimo, Louis B egin, Armen Aprikian, Simone Chevalier, Montreal, Canada INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) is a leading cause of cancer deaths in USA. There is no cure for advanced disease; patients failing surgery or radiations invariably fail androgendeprivation therapy (ADT) and further progress once castrate-resistant (CRPC). Studies point to anomalies in the androgen/androgen receptor (AR) axis in advanced PCa. We reported on the Fer tyrosine kinase directly activating AR on Y223 in PCa cells and becoming its partner in the tumor cell nucleus of CRPC patients (Rocha et al 2013) . We aimed to assess the pY223AR fate in PCa.
METHODS: Sections of human prostate tissues and metastases were stained using pY223AR antibodies (Abs) we raised, and N-and C-terminal Abs to detect all AR forms vs wild-type, respectively. Results were expressed in percentages (%) and H scores. The cohort included 450 cases ranging from healthy men to benign hyperplasia, prostatectomies, neo-adjuvant hormone therapy, advanced on ADT, primary/lymph nodes, bone metastases and seminal vesicles.
RESULTS: AR and pY223AR-negative tumor cells constituted up to 15% in ADT/CRPC cases. In AR positive epithelial cells of normal and benign cases, the AR staining was mainly nuclear but negative for pY223AR. In primary tumors, the AR intensity and H scores increased e1270
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